Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Dasabuvir. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.39 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 2/20 | 0.34 |
| ▸ | OGT | O15294 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 5/20 | 0.34 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.33 |
| ▸ | AR | P10275 | 1/20 | 0.33 |
| ▸ | DUT | P33316 | 2/20 | 0.33 |
| ▸ | PLAU | P00749 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.32 |
| ▸ | JAK1 | P23458 | 1/20 | 0.32 |
| ▸ | TYK2 | P29597 | 1/20 | 0.32 |
| ▸ | JAK3 | P52333 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dasabuvir SCHEMBL29838781 | 1.00 | CRBN (1.00) | CRBNCYP3A4BRPF1TP53OGT | |
| Dasabuvir SCHEMBL29362730 | 1.00 | CRBN (1.00) | CRBNCYP3A4BRPF1TP53OGT | |
| Dasabuvir SCHEMBL31554838 | 1.00 | CRBN (1.00) | CRBNCYP3A4BRPF1TP53OGT | |
| Dasabuvir SCHEMBL2367895 | 0.99 | CRBN (0.98) | CRBNCYP3A4BRPF1TP53OGT | |
| Dasabuvir SCHEMBL2368377 | 0.99 | CRBN (0.98) | CRBNCYP3A4BRPF1TP53OGT | |
| Dasabuvir SCHEMBL2367923 | 0.99 | CRBN (0.98) | CRBNCYP3A4BRPF1TP53OGT | |
| Dasabuvir SCHEMBL2368084 | 0.99 | CRBN (0.98) | CRBNCYP3A4BRPF1TP53OGT | |
| Dasabuvir SCHEMBL12537982 | 0.99 | CRBN (0.98) | CRBNCYP3A4BRPF1TP53OGT | |
| Dasabuvir SCHEMBL2367922 | 0.99 | CRBN (0.98) | CRBNCYP3A4BRPF1TP53OGT | |
| Dasabuvir SCHEMBL2367744 | 0.99 | CRBN (0.98) | CRBNCYP3A4BRPF1TP53OGT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 267 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10201542-B2 | Formulations of pyrimidinedione derivative compounds | ABBVIE INC. (US) | 2019-02-12 | — | — | US | claimed |
| US-9732045-B2 | Process for preparing antiviral compounds | ABBVIE INC. (US) | 2017-08-15 | — | — | US | claimed |
| US-20170181973-A1 | FORMULATIONS OF PYRIMIDINEDIONE DERIVATIVE COMPOUNDS | ABBVIE INC. | 2017-06-29 | — | — | US | claimed |
| US-9629841-B2 | Formulations of pyrimidinedione derivative compounds | ABBVIE INC. (US) | 2017-04-25 | — | — | US | claimed |
| US-20160332973-A1 | PROCESS FOR PREPARING ANTIVIRAL COMPOUNDS | ABBVIE INC. | 2016-11-17 | — | — | US | claimed |
| US-9434698-B2 | Process for preparing antiviral compounds | ABBVIE INC. (US) | 2016-09-06 | — | — | US | claimed |
| EP-2639226-B1 | Anti-infective pyrimidines and uses thereof | ABBVIE BAHAMAS LTD (BS) | 2016-08-31 | — | — | EP | claimed |
| EP-2593439-B1 | PROCESS FOR PREPARING ANTIVIRAL COMPOUNDS | ABBVIE BAHAMAS LTD (BS) | 2016-08-17 | — | — | EP | claimed |
| US-9139536-B2 | Anti-infective agents and uses thereof | ABBVIE INC. (US) | 2015-09-22 | — | — | US | claimed |
| US-20150191437-A1 | PROCESS FOR PREPARING ANTIVIRAL COMPOUNDS | ABBVIE INC. (US) | 2015-07-09 | — | — | US | claimed |
| US-8501238-B2 | Anti-infective agents and uses thereof | ABBVIE INC. (US) | 2013-08-06 | — | — | US | claimed |
| US-20120244119-A1 | ANTI-INFECTIVE AGENTS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2012-09-27 | — | — | US | claimed |
| US-20120213733-A1 | ANTI-INFECTIVE AGENTS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2012-08-23 | — | — | US | claimed |
| US-8188104-B2 | Anti-infective agents and uses thereof | ABBOTT LABORATORIES (US) | 2012-05-29 | — | — | US | claimed |
| US-20120014913-A1 | PROCESS FOR PREPARING ANTIVIRAL COMPOUNDS | ABBOTT LABORATORIES (US) | 2012-01-19 | — | — | US | claimed |
| EP-2368882-A1 | ANTI-INFECTIVE PYRIMIDINES AND USES THEREOF | ABBOTT LABORATORIES (US) | 2011-09-28 | — | — | EP | claimed |
| EP-2203431-B1 | ANTI-INFECTIVE PYRIMIDINES AND USES THEREOF | ABBOTT LAB (US) | 2011-08-10 | — | — | EP | claimed |
| EP-2203431-A1 | ANTI-INFECTIVE PYRIMIDINES AND USES THEREOF | Abbott Laboratories (US) | 2010-07-07 | — | — | EP | claimed |
| US-20090186912-A1 | ANTI-INFECTIVE AGENTS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2009-07-23 | — | — | US | claimed |
| WO-2009039134-A1 | ANTI-INFECTIVE PYRIMIDINES AND USES THEREOF | ABBOTT LABORATORIES (US) | 2009-03-26 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170181973-A1 | FORMULATIONS OF PYRIMIDINEDIONE DERIVATIVE COMPOUNDS | DPYD, TYMP, TYMS | CRBN 4474/4885CYP3A4 277/4885BRPF1 2345/4885 |
| US-20120213733-A1 | ANTI-INFECTIVE AGENTS AND USES THEREOF | MPO, SERPINB1, ELANE | CRBN 3902/4885CYP3A4 1675/4885BRPF1 2988/4885 |
| US-20120244119-A1 | ANTI-INFECTIVE AGENTS AND USES THEREOF | MPO, SERPINB1, ELANE | CRBN 3902/4885CYP3A4 1675/4885BRPF1 2988/4885 |
| US-10201542-B2 | Formulations of pyrimidinedione derivative compounds | DPYD, TYMP, TYMS | CRBN 4474/4885CYP3A4 277/4885BRPF1 2345/4885 |
| US-20160332973-A1 | PROCESS FOR PREPARING ANTIVIRAL COMPOUNDS | HAVCR2, RNASE1, MAVS | CRBN 2554/4885CYP3A4 155/4885BRPF1 2952/4885 |
| US-20120014913-A1 | PROCESS FOR PREPARING ANTIVIRAL COMPOUNDS | HAVCR2, MAVS, RNASE1 | CRBN 2709/4885CYP3A4 173/4885BRPF1 2956/4885 |
| US-20090186912-A1 | ANTI-INFECTIVE AGENTS AND USES THEREOF | MPO, SERPINB1, ELANE | CRBN 3902/4885CYP3A4 1675/4885BRPF1 2988/4885 |
| US-20150191437-A1 | PROCESS FOR PREPARING ANTIVIRAL COMPOUNDS | HAVCR2, RNASE1, MAVS | CRBN 2554/4885CYP3A4 155/4885BRPF1 2952/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.